AKT1 and ovarian carcinoma: As increasing numbers of AKT inhibitors are advancing to clinical trial for treatment of advanced solid malignancies, including ovarian cancer, a number of trials in particular have focused on targeting recurrent chemotherapy-resistant ovarian cancer patients based on pre-clinical evidence of efficacy.